Department of Pediatric, Dicle University School of Medicine, Diyarbakir, Turkey.
Department of Pediatric Pulmonology, Dicle University School of Medicine, Diyarbakir, Turkey.
Pediatr Pulmonol. 2020 Dec;55(12):3595-3601. doi: 10.1002/ppul.25106. Epub 2020 Oct 13.
Coronavirus disease 2019 (COVID-19) is a global health problem that can result in serious complications. The aim of this study was to investigate the prevalence and clinical importance of vitamin D deficiency in children with COVID-19.
This study includes 40 patients who were diagnosed to have COVID-19 and hospitalized with the real-time reverse transcription polymerase chain reaction method, 45 healthy matched control subjects with vitamin D levels. The age of admission, clinical and laboratory data, and 25-hydroxycholecalciferol (25-OHD) levels were recorded. Those with vitamin D levels which are below 20 ng/ml were determined as Group 1 and those with ≥20 ng/ml as Group 2.
Patients with COVID-19 had significantly lower vitamin D levels 13.14 μg/L (4.19-69.28) than did the controls 34.81 (3.8-77.42) μg/L (p < .001). Patients with COVID-19 also had significantly lower serum phosphorus (4.09 ± 0.73 vs. 5.06 ± 0.93 vs. (U/L) (p < .001)) values compared with the controls. The symptom of fever was significantly higher in COVID- 19 patients who had deficient and insufficient vitamin D levels than in patients who had sufficient vitamin D levels (p = .038). There was a negative correlation found between fever symptom and vitamin D level (r = -0.358, p = .023).
This is the first to evaluate vitamin D levels and its relationship with clinical findings in pediatric patients with COVID-19. Our results suggest that vitamin D values may be associated with the occurrence and management of the COVID-19 disease by modulating the immunological mechanism to the virus in the pediatric population.
2019 年冠状病毒病(COVID-19)是一个全球性的健康问题,可能导致严重的并发症。本研究旨在调查儿童 COVID-19 患者维生素 D 缺乏症的患病率和临床重要性。
本研究包括 40 名通过实时逆转录聚合酶链反应方法诊断为 COVID-19 并住院的患者和 45 名维生素 D 水平匹配的健康对照者。记录入院时的年龄、临床和实验室数据以及 25-羟胆钙化醇(25-OHD)水平。维生素 D 水平低于 20ng/ml 的患者被确定为第 1 组,水平≥20ng/ml 的患者被确定为第 2 组。
COVID-19 患者的维生素 D 水平明显低于对照组,分别为 13.14μg/L(4.19-69.28)和 34.81μg/L(3.8-77.42)(p<0.001)。COVID-19 患者的血清磷(4.09±0.73 vs. 5.06±0.93 vs. (U/L)(p<0.001))值也明显低于对照组。维生素 D 水平不足和不足的 COVID-19 患者的发热症状明显高于维生素 D 水平充足的患者(p=0.038)。发热症状与维生素 D 水平之间存在负相关关系(r=-0.358,p=0.023)。
这是首次评估儿科 COVID-19 患者的维生素 D 水平及其与临床发现的关系。我们的结果表明,维生素 D 值可能通过调节免疫机制与病毒相互作用,与 COVID-19 疾病的发生和治疗有关。